About this episode
The episode discusses the benefits and potential risks associated with GLP-1 inhibitors like Ozempic.
A new class of drugs, GLP-1 inhibitors (Ozempic being the most recognizable) has seemingly taken the world by storm. If the hype is to be believed, there seems to be enormous upsides and zero downsides to these new wonders of chemistry. Is that really the case, or might there be reason for caution? Join the Gwartney Institute for an insightful discussion on the promise and perils of these powerful peptides.
Topics covered
- GLP-1 inhibitors
- Ozempic
- health
- pharmaceuticals
- chemistry
Keywords
- drugs
- healthcare
- medication
- weight loss
Mentioned in this episode
Products: Ozempic
More episodes of Faith and Economics
- LEGO Lawfare | #396 · June 8, 2026 · 43 min
- Shrinking Middle Class? | #395 · June 1, 2026 · 36 min
- Gerrymandering, not as a bad as you think | #394 · May 25, 2026 · 34 min
- Tragedy | #393 · May 18, 2026 · 35 min
- Button, Button…| #392 · May 11, 2026 · 33 min
- Rational Ignorance and Public Choice | #201 · May 4, 2026 · 38 min
Explore listener stats, chart rankings, contacts and more on the Faith and Economics podcast page.